An interventional study of Aromatherapy inhaler and Aromatherapy inhaler (placebo) in Chemotherapy-Induced Nausea and Vomiting (CINV), sponsored by Singapore General Hospital. Enrolling by invitation at 1 site in Singapore. Open to participants aged 21 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-12-22.
Sponsored by Singapore General Hospital · Not applicable, Interventional, and Supportive care
The goal of this clinical trial is to evaluate whether aromatherapy inhaler sticks can reduce nausea and vomiting in patients receiving chemotherapy as part of their stem cell transplant treatment. The main questions it aims to answer are:
Researchers will compare patients using aromatherapy inhaler sticks with essential oils to patients using inhaler sticks with only jojoba oil (placebo) to see if the essential oils provide additional benefits for reducing nausea and vomiting.
Participants will:
793 studies on the registry are indexed under Vomiting; 99 are open to participants now.
This study's planned enrollment of 30 is below the median of 103 across 673 interventional studies indexed under Vomiting.
Browse Vomiting studies →Singapore General Hospital is the lead sponsor of 270 studies on the registry; 57 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in the control group will receive the placebo intervention in addition to standard care. Participants will be provided with an identical aromatherapy inhaler stick infused solely with jojoba oil. Jojoba oil, primarily used as a carrier oil for dilution, has little to- no scent and no known therapeutic or anxiolytic effects when inhaled. This ensures that any potential benefits observed in the intervention group can be attributed to the active essential oil blends rather than the inhalation process itself.
Other: Aromatherapy inhaler (placebo)
Participants in the intervention group will receive inhalation therapy via an aromatherapy inhaler stick\*, on top of standard care. Participants will be instructed to use the inhaler stick every four hours when they are awake, and whenever they feel nauseous, by holding the inhaler stick a finger's length away from their nostrils and inhaling through one nostril at a time. Each administration should not last more than 5 minutes. Participants will commence using the inhaler stick on the day of chemotherapy, until five days after the completion of chemotherapy (a total of six days).
Other: Aromatherapy inhaler
Participants in the intervention group will receive inhalation therapy via an aromatherapy inhaler stick\*, on top of standard care. Participants will be instructed to use the inhaler stick every four hours when they are awake, and whenever they feel nauseous, by holding the inhaler stick a finger's length away from their nostrils and inhaling through one nostril at a time. Each inhaler administration should not last more than 5 minutes. Participants will commence using the inhaler stick on the day of chemotherapy, until five days after the completion of chemotherapy (total of six days). Given the subjective nature of scents, participants in the intervention group will be given a choice between two therapeutic aroma blends - N1 and N2 - before commencing the study. This approach aims to minimize the risk of negative associations with a particular scent and enhance participant adherence to the intervention.
Participants in the control group will receive the placebo intervention in addition to standard care. They will be provided with an identical aromatherapy inhaler stick infused solely with jojoba oil. Jojoba oil, primarily used as a carrier oil for dilution, has littleto- no scent and no known therapeutic or anxiolytic effects when inhaled.
Recruitment Rate
Percentage of eligible patients who consent to join the study will be measured to evaluate the feasibility of using inhalation aromatherapy to reduce chemotherapy-induced nausea and vomiting (CINV) for patients undergoing haematopoietic stem cell transplant (HSCT)
Time frame: From commencement of study (Day 1) to the end of treatment (Day 6)
Retention Rate
Percentage of participants who complete the study will be measured to evaluate the feasibility of using inhalation aromatherapy to reduce chemotherapy-induced nausea and vomiting (CINV) for patients undergoing haematopoietic stem cell transplant (HSCT)
Time frame: From commencement of study (Day 1) to the end of treatment (Day 6)
Adherence rate
Percentage of participants in the intervention group who use the inhaler stick as instructed measured to evaluate the feasibility of using inhalation aromatherapy to reduce chemotherapy-induced nausea and vomiting (CINV) for patients undergoing haematopoietic stem cell transplant (HSCT)
Time frame: From commencement of study (Day 1) to the end of treatment (Day 6)
Patient-reported satisfaction
Measured through Likert-scale items at the end of the study to evaluate the acceptability of using inhalation aromatherapy to reduce chemotherapy-induced nausea and vomiting (CINV) for patients undergoing hematopoietic stem cell transplant (HSCT). The Feasibility of intervention Likert-scale and the Acceptability of intervention Liker-scale will be used. The Likert-scale consist of a rating of 1- 5 where 1 is strongly disagree and 5 is strongly agree and to be rated by participants.
Time frame: From commencement of study (Day 1) to the end of treatment (Day 6)
Perceptions and Overall Experience
Qualitative insights from semi-structured interviews on ease of use, perceived helpfulness and overall experience to evaluate acceptability of using inhalation aromatherapy to reduce chemotherapy-induced nausea and vomiting (CINV) for patients undergoing haematopoietic stem cell transplant (HSCT)
Time frame: From commencement of study (Day 1) to the end of treatment (Day 6)
Severity of Nausea
Patient-reported nausea severity measured daily using a Visual Analog Scale (VAS, 0 = no nausea, 10 = worst possible nausea).
Time frame: From commencement of study (Day 1) to the end of treatment (Day 6)
Frequency of Vomiting
Number of vomiting episodes recorded in patient journals and verified against electronic medical records
Time frame: From commencement of study (Day 1) to the end of treatment (Day 6)
Use of Rescue Anti-Emetics
Frequency and dosage of rescue anti-emetic medication administered, retrieved from electronic medical records
Time frame: From commencement of study (Day 1) to the end of treatment (Day 6)
Oral Intake
Daily oral intake as documented in medical records as an indicator of nausea levels
Time frame: From commencement of study (Day 1) to end of treatment (Day 6)
Grading of Chemotherapy-Induced Nausea and Vomiting (CINV)
Grading of CINV severity using the Common Terminology Criteria for Adverse Events (CTCAE v5.0) on a 0-4 scale, where higher scores indicate more severe symptoms
Time frame: From commencement of study (Day 1) to end of treatment (Day 6)
Plan to share: Undecided
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for Jun 2026, 13 months after the start.
Of 131 non-industry interventional studies with no phase under Vomiting, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 29. This study's planned 13 months is close to that.
Counting every sponsor, half of 134 studies reached it within 13 months; a quarter within 6 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.